



Patent
Attorney's Docket No. 003300-712

TECH CENTER 1600/2900

FEB 06 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Kjell OLMARKER et al.) Group Art Unit: 1646
Application No.: 09/743,852) Examiner: Eileen B. O'Hara
Filed: January 17, 2001)
For: USE OF CERTAIN DRUGS FOR)
TREATING NERVE ROOT INJURY)

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action of January 8, 2002, Applicants elect with traverse the claims of Group I (i.e., Claims 35 to 52) drawn to a method for treating nerve disorders in a mammal.

Applicants further elect monoclonal antibodies and spinal disorder. This election would correspond to part of Claim 35 relating to (ii) monoclonal antibody that blocks TNF- α , Claim 36, Claim 38, Claim 43, and Claims 46 to 50.

It respectfully is urged that all claims could be conveniently prosecuted in a single application. It further should be recognized that this Application is a national phase filing of International Application No. PCT/SE99/01671 filed September 23, 1999. During the international phase of examination unity of invention already has been confirmed.

Applicants further regard all the TNF- α inhibitors and all the nerve disorders, respectively, to constitute a single inventive concept and all generic claims should accordingly be allowable.

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Benton S. Duffett Jr.
Benton S. Duffett, Jr.
Registration No. 22,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Filed: February 4, 2002